7-hydroxy-2-n,n-dipropylaminotetralin has been researched along with Benign Essential Tremor in 1 studies
7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET)." | 7.83 | Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. ( Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2016) |
| "The aim of the study was to examine the effects of preferential agonists of dopamine D3 receptors: pramipexole and 7-OH-DPAT on the harmaline-induced tremor in rats (a model of essential tremor, ET)." | 3.83 | Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats. ( Ananthan, S; Głowacka, U; Kosmowska, B; Ossowska, K; Wardas, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kosmowska, B | 1 |
| Wardas, J | 1 |
| Głowacka, U | 1 |
| Ananthan, S | 1 |
| Ossowska, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for 7-hydroxy-2-n,n-dipropylaminotetralin and Benign Essential Tremor
| Article | Year |
|---|---|
Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.
Topics: Amisulpride; Animals; Anti-Dyskinesia Agents; Benzothiazoles; Disease Models, Animal; Dopamine Agoni | 2016 |